Navigation Links
GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)
Date:10/5/2009

PHILADELPHIA, Oct. 5 /PRNewswire/ -- GlaxoSmithKline [NYSE: GSK] today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.

"Kidney cancer is a very serious disease therefore the committee's recommendation in support of pazopanib is an important step towards bringing a new, oral treatment option to advanced renal cell cancer patients," said Rafael Amado, MD, Vice President, GlaxoSmithKline Oncology R&D Unit. "We look forward to working with the FDA towards the approval of pazopanib."

RCC is the most common type of kidney cancer and accounts for approximately nine out of ten cases. It is estimated that approximately 57,700 people will be diagnosed with kidney cancer and 13,000 people will die from kidney cancer in the United States in 2009. In 2002, an estimated 208,000 new cases of kidney cancer were diagnosed globally.

The advisory committee made its decision based on Phase III pivotal trial data that were presented at the American Society of Clinical Oncology 2009 annual meeting.

About pazopanib

Pazopanib is an investigational medicine that may prevent the growth of new blood vessels to tumors, a process known as angiogenesis. All solid tumors need blood vessels to survive, and medicines in this category may halt the progression of tumor growth.

About pazopanib and clinical development

In its pivotal study, pazopanib was administered orally, once daily. Pazopanib has a broad clinical program across multiple tumor types, with study details available at www.clinicaltrials.gov. Mo
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
2. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
3. FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmabs ARZERRA(TM) (ofatumumab)
4. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
5. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
6. Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline
7. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
8. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
9. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
10. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
11. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015 Today, UBM China, a ... agreement with Chengdu Tianyi Exhibition Co., Ltd. to jointly ... is to be held concurrently with CWMEE 2016. ... healthcare exhibition family, following MEDTEC China and DENTECH China, ... in west China. It,s also another concrete cooperative project ...
(Date:6/30/2015)... und KOPENHAGEN, Dänemark, 30. Juni 2015 /PRNewswire/ ... Weltmarktführer der klinischen und kommerziellen Produktion von ... heute bekannt, dass das Unternehmen im Rahmen ... der nordamerikanischen Produktionsanlage in Bothell, ... Einweg-Anlage Bioreactor 6Pack™ komplettiert hat. Die Konfiguration ...
(Date:6/30/2015)... 2015  EnteroMedics Inc. (NASDAQ: ETRM ), a ... to treat obesity, metabolic diseases, and other gastrointestinal disorders, ... of 40,229,886 units. Each unit consists of one share ... to purchase one share of common stock, and 0.50 ... of common stock, at a purchase price of $0.87 ...
Breaking Medicine Technology:UBM Joins Chengdu Tianyi to Hold CWMEE 2016 2UBM Joins Chengdu Tianyi to Hold CWMEE 2016 3CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3
... Inc. (Nasdaq: OPTR ) today announced it expects ... after the NASDAQ Global Market closes on Thursday, March 10, ... that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ... fourth quarter and full year 2010, as well as provide ...
... CRANBURY, N.J., March 3, 2011 Palatin Technologies, Inc. (NYSE ... Food and Drug Administration (FDA) has cleared Palatin,s request to ... New Drug (IND) application using a subcutaneously administered formulation of ... acute exacerbations of asthma. "We are excited ...
Cached Medicine Technology:Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results 2FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for Asthma 2
(Date:6/30/2015)... ... June 30, 2015 , ... Fireside ... Convalescent Care Center.” The video informs community members of Fireside’s Five-Star Medicare ranking ... need for those seeking care to be well informed and confident about making ...
(Date:6/30/2015)... ... June 30, 2015 , ... Retail Management Solutions ... tradeshow, taking place July 29 to August 1. Retail Management Solutions will be ... is a four-day event for independent community pharmacies, where they receive practical ...
(Date:6/30/2015)... ... 30, 2015 , ... According to a recent report by the U.S. Drug ... more than tripled in the same period—leading a majority of law enforcement agencies to ... a leading Florida-based drug treatment facility, asserts that these heroin statistics point to an ...
(Date:6/30/2015)... ... June 30, 2015 , ... According to a June 15th report ... to study how sensory stimuli can be used to “decrease children’s anxiety and negative ... children with autism, will compare patient experience in a “typical dental environment” with one ...
(Date:6/30/2015)... ... June 30, 2015 , ... Lakeview Health, a drug and ... size of its medical staff to further enhance its ability to treat addiction ... practitioners and physician assistants -- now totals 17, compared to 7 in 2013, ...
Breaking Medicine News(10 mins):Health News:Fireside Convalescent Hospital Proves Itself as a Leading Care Center in New Video 2Health News:Retail Management Solutions to Attend Amerisource's ThoughtSpot 2015 Conference and Trade Show 2Health News:Retail Management Solutions to Attend Amerisource's ThoughtSpot 2015 Conference and Trade Show 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2
... DIEGO, Aug. 11 CardioDynamics (Nasdaq: CDIC ), the ... at a special meeting held today, the shareholders of CardioDynamics voted ... 2009, by and among CardioDynamics, SonoSite, Inc. (Nasdaq: SONO ... a wholly owned subsidiary of SonoSite. , , ...
... NORTHFIELD, Ill., Aug. 11 Today, Kraft Foods Inc. ... company to use the Smart Choices Program nutrition criteria ... the United States. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090420/KRAFTLOGO ... is a voluntary nutrition labeling system designed to help shoppers ...
... Older adults who ate healthy and remained active were ... -- Eating a Mediterranean diet, which emphasizes fruits, vegetables, ... can reduce the risk of developing Alzheimer,s disease, a ... the Aug. 12 issue of the Journal of ...
... workers recognized fewer than half of household hazards in study ... children identified fewer than half of the potential safety hazards ... either health-care professionals or day-care workers, a new study finds. ... found that the mothers and fathers recognized fewer hazards when ...
... TAMPA, Fla., Aug. 11 As college football rivalries heat up ... out the tailgating grills, the spinal experts at Tampa,s Laser ... take care of their spines. Twenty percent of sports-related injuries affect ... active lifestyle, from the weekend warrior to the professional athlete, should ...
... conducted in Europe found that the vast majority of ... cancer screening, according to a new study published online ... Cancer Institute . Gerd Gigerenzer, of the Max ... conducted a survey of over 10,200 people from nine ...
Cached Medicine News:Health News:CardioDynamics Shareholders Approve Merger Agreement with SonoSite 2Health News:CardioDynamics Shareholders Approve Merger Agreement with SonoSite 3Health News:Kraft Foods First Company to Adopt Smart Choices Program Nutrition Criteria for Advertising to Children in the U.S. 2Health News:Mediterranean Diet Plus Exercise Lowers Alzheimer's Risk 2Health News:Mediterranean Diet Plus Exercise Lowers Alzheimer's Risk 3Health News:Many Parents, Caregivers Lack Basic Child-Safety Information 2Health News:Spike Footballs this Fall Without Straining the Spine 2
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Antelys Peek Lumbar Technologies provides a range of varied heights and angles to correct lumbar lordosis and the associated sagital balance....
Spectrum Dynamics empowers Nuclear Imaging with the SmartR Technology,of the D-SPECT Cardiac Imaging System. The D-SPECT is powered by BroadView Technology to provide unprecedented throughput, whil...
For immediate disabling...
Medicine Products: